OncoSec Medical (NASDAQ:ONCS) has been assigned a $5.00 target price by investment analysts at Maxim Group in a report released on Thursday, March 15th. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Maxim Group’s price target would indicate a potential upside of 142.72% from the company’s current price.
A number of other analysts have also recently weighed in on the company. HC Wainwright set a $6.00 price target on OncoSec Medical and gave the stock a “buy” rating in a research report on Friday, December 15th. Piper Jaffray initiated coverage on OncoSec Medical in a research report on Friday, February 9th. They set an “overweight” rating and a $4.00 price target on the stock. Finally, ValuEngine cut OncoSec Medical from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $5.00.
Shares of OncoSec Medical stock opened at $2.06 on Thursday. The company has a market cap of $110.17, a PE ratio of -1.94 and a beta of 3.05. OncoSec Medical has a twelve month low of $0.88 and a twelve month high of $2.95.
OncoSec Medical (NASDAQ:ONCS) last announced its quarterly earnings results on Friday, March 9th. The biotechnology company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.05). research analysts predict that OncoSec Medical will post -0.73 earnings per share for the current fiscal year.
In other OncoSec Medical news, CEO Daniel J. O’connor bought 16,667 shares of the stock in a transaction that occurred on Monday, February 5th. The shares were purchased at an average cost of $1.50 per share, for a total transaction of $25,000.50. Following the transaction, the chief executive officer now directly owns 16,667 shares in the company, valued at $25,000.50. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.50% of the stock is owned by company insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. MYDA Advisors LLC acquired a new stake in OncoSec Medical in the 4th quarter valued at approximately $145,000. J. Goldman & Co LP acquired a new stake in OncoSec Medical in the 4th quarter valued at approximately $163,000. Deutsche Bank AG acquired a new stake in OncoSec Medical in the 4th quarter valued at approximately $261,000. Finally, Renaissance Technologies LLC acquired a new stake in OncoSec Medical in the 4th quarter valued at approximately $272,000. Hedge funds and other institutional investors own 8.72% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This article was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark law. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/07/oncosec-medical-oncs-given-a-5-00-price-target-at-maxim-group.html.
About OncoSec Medical
OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.
Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.